Lilly’s push into pain research starting to pay off
In recent months, the drugmaker has won federal approval to sell a drug called Emgality for two conditions: migraine pain and cluster headaches.
Eli Lilly and Co.
Articles
Pfizer expanding in cancer with $10.6B deal for Array BioPharma
Array’s stock was already at a record before the deal announcement, following the company’s news last month of positive clinical trial results using Braftovi and Mektovi with Indianapolis-based Eli Lilly and Co.’s Erbitux.
Drugmakers sue Trump administration to halt advertising rule
Some of the biggest pharmaceutical companies, including Indianapolis-based Eli Lilly and Co., sued the Trump administration to try and block a rule that would force them to put the price of their drugs in television advertisements.
Q&A with Tiffany Benjamin: Lilly’s efforts more than simply a day of service
“Our central focus as a company is always to make lives better. … It’s a value that is core to every single employee who works here. So if we can have programs that reinforce that we are a company that is focused on making lives better, then we are doing something that connects to our mission and reminds our employees what really matters to us as a company.”
Lilly pain drug wins approval to treat cluster headaches
It’s the second approved use for Emgality, which first won U.S. approval last fall to treat migraines. Analysts predict it could become a blockbuster.
China to audit 77 drugmakers, including Lilly, after $4.3B scandal
After one of its largest listed drug makers was found to have overstated its cash position by $4.3 billion, China is starting an audit of 77 major pharmaceutical companies.
Lilly begins selling half-price version of popular Humalog insulin
The fast-acting insulin, which diabetics inject shortly before each meal, is used by about 700,000 Americans.
Eli Lilly shares droop after drugmaker lowers full-year outlook
Indianapolis-based Lilly reported first quarter revenue of $5.09 billion, up 3% from a year ago but below analyst expectations of $5.2 billion. Sales of several of Lilly’s top drugs missed expectations.
Elanco agrees to buy pet-drug developer for $234 million
Kansas-based Aratana Therapeutics has three treatments approved by the U.S. Food and Drug Administration and is working on drugs for a range of disease fields, including cancer.
Lilly creates public downtown park on edge of its headquarters campus
The city’s newest park is springing up on the south side of downtown, a district quickly filling up with apartments, offices and retail—and a noticeable shortage of public green space.
Drugmakers reveal list prices online after pressure from Trump
Indianapolis-based Eli Lilly and Co. was one of the first drug firms to begin sharing prices. Now, others are following suit.
Lilly bets billions on focus on cancer drugs
Long a leader in diabetes and neuroscience drugs, Eli Lilly and Co. is pushing hard and spending record sums to turbocharge its oncology business, potentially a huge growth area.
Group with consumer-friendly vibe pushes drugmakers’ message
As Congress and President Donald Trump's administration aim to lower prescription drug costs, outside groups like the Alliance for Patient Access are seeking to sway the outcome.
Lilly’s $7M tax-abatement request advanced by City-County Council panel
The proposed tax abatement is related to a $91 million investment the company is making in a building at the Lilly Technology Center on Kentucky Avenue.
Lilly to introduce generic version of insulin at half off Humalog’s list price
The move comes at a time drug makers, especially those that make insulin, are facing withering criticism for raising prices.
Lilly, other insulin makers must face price-gouging lawsuit, judge rules
The suit accuses the companies of raising insulin sticker prices by more than 150 percent over five years, forcing diabetics to forgo the drug, take less insulin than needed or use expired versions
Eli Lilly negotiated its largest deal ever at breakneck speed
When the Indianapolis-based drug giant made its initial offer Dec. 20, it said it wanted to seal the deal before the J.P. Morgan Healthcare Conference, which ran Jan. 7-10 in San Francisco.
Lilly shares dip due to drug failure, lowered forecast
The Indianapolis-based pharmaceutical giant on Wednesday tempered expectations for its earnings in 2019 after a promising cancer drug failed to pan out and the firm prepared for big acquisition.
Harvard study involving Anthem unit finds older insulins are both safe, cheaper
Increasingly, top researchers are questioning whether drugs such as Lantus from Sanofi, Levemir and Novolog from Novo Nordisk A/S, and Humalog from Eli Lilly and Co. are really needed for many patients.
Lilly cancer drug shouldn’t be started in new patients, FDA says
Lartruvo shouldn’t be started in new patients, and those patients already taking it should ask their doctors if they should continue, U.S. regulators said, following a key study that failed to show the medicine prolonged lives.